CME in Minutes: Education in Ophthalmology - Christine E. Jones, BMBS, PhD - Preventing Congenital Cytomegalovirus Through Behavioral and Emerging Vaccination Strategies

Christine E. Jones, BMBS, PhD - Preventing Congenital Cytomegalovirus Through Behavioral and Emerging Vaccination Strategies

03/27/23 • 13 min

CME in Minutes: Education in Ophthalmology

Please visit answersincme.com/BZR860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in pediatric infectious diseases discusses prevention of congenital cytomegalovirus (cCMV). Upon completion of this activity, participants should be better able to: Recognize the disease burden of congenital cytomegalovirus; Describe the rationale for novel vaccines in preventing congenital cytomegalovirus; and Outline evidence-based strategies to improve neonatal outcomes in congenital cytomegalovirus.

Previous Episode

George Oral Waring IV, MD, FACS - Up Close With Presbyopia: Novel Emerging Miotic Agents for Aging Eyes

Please visit answersincme.com/EUA860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in ophthalmology discusses new treatments for patients with presbyopia. Upon completion of this activity, participants should be better able to:Recognize the unmet therapeutic needs with available presbyopia treatments; Describe the evidence for late-stage emerging miotic agents being developed to treat presbyopia; and Outline strategies to individualize treatment selection for patients with presbyopia.

Next Episode

Yasha Modi, MD / Christina Y. Weng, MD, MBA - Weighing Out the Risks and Benefits of Intravitreal Anti-VEGF Injections for nAMD

Please visit answersincme.com/XVY860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in ophthalmology discuss intravitreal anti–vascular endothelial growth factor (VEGF) injections for neovascular age-related macular degeneration (nAMD). Upon completion of this activity, participants should be better able to: Describe the latest evidence for anti-vascular endothelial growth factor (anti-VEGF) therapies used in the treatment of nAMD; and Outline practical strategies to optimize the use of anti-VEGF therapies in the management of nAMD.